- Home
- NSTS vs ALXO Comparison
NSTS vs ALXO Comparison
Compare NSTS & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | ALXO |
|---|---|---|
| Founded | 1921 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.4M | 68.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NSTS | ALXO |
|---|---|---|
| Price | $12.50 | $2.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.42 |
| AVG Volume (30 Days) | 1.5K | ★ 886.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $256,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.73 | $0.41 |
| 52 Week High | $13.06 | $2.66 |
Technical Indicators
Market Signals| Indicator | NSTS | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 66.55 |
| Support Level | $12.19 | $2.20 |
| Resistance Level | $12.26 | $2.66 |
| Average True Range (ATR) | 0.16 | 0.31 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 19.64 | 82.18 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.